Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Issue 1 (23rd June 2014)

• Record Type: Journal Article
• Authors: Lip, Gregory Y.H.; Laroche, Cécile; Boriani, Giuseppe; Cimaglia, Paolo; Dan, Gheorghe-Andrei; Santini, Massimo; Kalarus, Zbigniew; Rasmussen, Lars Hvilsted; Popescu, Mircea Ioachim; Tica, Otilia; Hellum, Camilla Fragtrup; Mortensen, Bettina; Tavazzi, Luigi; Maggioni, Aldo P.
• Is Part Of: Europace. Volume 17:Issue 1(2015:Jan.)
• Page Start: 24
• Page End: 31
• Publication Date: 2014-06-23
• Subjects: Atrial fibrillation -- Female -- Anticoagulation -- Survey; Arrhythmia -- Treatment -- Periodicals; Cardiac pacing -- Periodicals; Catheter ablation -- Periodicals; Heart -- Physiology -- Periodicals; Electrophysiology -- Periodicals; 617.4120645
• DOI: 10.1093/europace/euu155
• Languages: English
• ISSNs: 1099-5129

Abstract

Abstract : Aims: Sex differences in the epidemiology and clinical management of AF are evident. Of note, females are more symptomatic and if age >65, are at higher risk of thromboembolism if incident AF develops, compared with males. Methods and results: In an analysis from the dataset of the Euro Observational Research Programme on Atrial Fibrillation (EORP-AF) Pilot survey ( n = 3119), we examined sex-related differences in presentation, treatment, and outcome of contemporary patients with AF in Europe.Female subjects were older ( P < 0.0001), with a greater proportion aged ≥75 years, with more heart failure and hypertension. Heart failure with preserved ejection fraction was more common in females ( P < 0.0001), as was valvular heart disease ( P = 0.0003). Females were more symptomatic compared with males with a higher proportion being EHRA Class III and IV ( P = 0.0012). The more common symptoms that were more prevalent in females were palpitations ( P < 0.0001) and fear/anxiety ( P = 0.0007). Other symptoms (e.g. dyspnoea, chest pain, fatigue, etc.) were not different between males and females. Health status scores were significantly lower for females overall, specifically for the psychological and physical domains (both P < 0.0001) but not for the sexual activity domain ( P = 0.9023). Females were less likely to have electrical cardioversion (18.9 vs. 25.5%, P < 0.0001), and more likely to receive rate control ( P = 0.002). Among patients recruited in hospital and discharged alive ( n = 2009), documented contraindications to vitamin K antagonist (VKA) were evident in 23.8% of females. A CHA2 DS2 -VASc score ≥2 was found in 94.7% of females and 74.6% of males ( P < 0.0001), with oral anticoagulants being used in 95.3 and 76.2%, respectively ( P < 0.0001). A HAS-BLED score of ≥3 was found in 12.2% of females and 14.5% of males. Independent predictors of VKA use in females on multivariate analysis were CHA2 DS2 -VASc score ( P = 0.0007), lower HAS-BLED score ( P = 0.0284), and prosthetic mechanical valves ( P = 0.0276). Conclusion: The EORP-AF Pilot survey provides contemporary data on sex differences in clinical features and management of AF patients participating in the EORP-AF Pilot registry. Female subjects were older and more symptomatic, compared with males, and were more likely to receive rate control. Also, female patients were at higher stroke risk overall, but oral anticoagulation was used in a high proportion of patients.